Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)

Description

The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and muscle capillary blood volume, improves vascular function in the larger conduit vessels, and enhances insulin's metabolic action in humans with Type 2 diabetes. Subjects will be randomized to one of the three groups: exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 16 weeks of intervention.

Conditions

Type2 Diabetes

Study Overview

Study Details

Study overview

The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and muscle capillary blood volume, improves vascular function in the larger conduit vessels, and enhances insulin's metabolic action in humans with Type 2 diabetes. Subjects will be randomized to one of the three groups: exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 16 weeks of intervention.

Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)

Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)

Condition
Type2 Diabetes
Intervention / Treatment

-

Contacts and Locations

Charlottesville

University of Virginia, Charlottesville, Virginia, United States, 22906

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 21-60
  • * A1C ≤ 8.5%
  • * Never on GLP-1RA (eg: exenatide, liraglutide) or DPP4I ( eg: Sitaglipton)
  • * On stable dose of oral hypoglycemic agents \>4 months
  • * On stable dose of other medications for \>4 months
  • * Taking Insulin
  • * Smoking presently or in the past 6 months
  • * BP \>160/90
  • * BMI \>35
  • * Family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome
  • * History of congestive heart failure, ischemic heart disease, severe pulmonary disease, liver or kidney disease.
  • * Any vascular disease such as myocardial infarction, stroke, peripheral vascular disease
  • * Presence of an intracardiac or intrapulmonary shunt (we will screen for this by auscultation during the physical exam by PI).
  • * Pregnant or breastfeeding.
  • * Known hypersensitivity to perflutren (contained in Definity)

Ages Eligible for Study

21 Years to 60 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Virginia,

Zhenqi Liu, MD, PRINCIPAL_INVESTIGATOR, University of Virginia, Department of Endocrinoolgy

Study Record Dates

2025-12